US9532990B2 - Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors - Google Patents

Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors Download PDF

Info

Publication number
US9532990B2
US9532990B2 US15/075,033 US201615075033A US9532990B2 US 9532990 B2 US9532990 B2 US 9532990B2 US 201615075033 A US201615075033 A US 201615075033A US 9532990 B2 US9532990 B2 US 9532990B2
Authority
US
United States
Prior art keywords
mmol
fluoro
pyrimidin
pyrazolo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/075,033
Other languages
English (en)
Other versions
US20160200730A1 (en
Inventor
Wei He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Green Pine Growth No 1 Equity Investment Partnerships (limited Partnership)
Original Assignee
Zhejiang Dtrm Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Dtrm Biopharma Co Ltd filed Critical Zhejiang Dtrm Biopharma Co Ltd
Publication of US20160200730A1 publication Critical patent/US20160200730A1/en
Assigned to Zhejiang DTRM Biopharma Co. Ltd. reassignment Zhejiang DTRM Biopharma Co. Ltd. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HE, WEI
Priority to US15/356,014 priority Critical patent/US9861636B2/en
Application granted granted Critical
Publication of US9532990B2 publication Critical patent/US9532990B2/en
Assigned to SHENZHEN GREEN PINE GROWTH NO. 1 EQUITY INVESTMENT PARTNERSHIPS (LIMITED PARTNERSHIP) reassignment SHENZHEN GREEN PINE GROWTH NO. 1 EQUITY INVESTMENT PARTNERSHIPS (LIMITED PARTNERSHIP) SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Zhejiang DTRM Biopharma Co. Ltd.
Priority to US15/820,614 priority patent/US10300066B2/en
Assigned to SHENZHEN GREEN PINE GROWTH NO. 1 EQUITY INVESTMENT PARTNERSHIPS (LIMITED PARTNERSHIP) reassignment SHENZHEN GREEN PINE GROWTH NO. 1 EQUITY INVESTMENT PARTNERSHIPS (LIMITED PARTNERSHIP) TERMINATION AND RELEASE OF PATENT ASSIGNMENT Assignors: Zhejiang DTRM Biopharma Co. Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/29—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Definitions

  • BTK Bruton tyrosine kinase
  • PH pleckstrin homology
  • TH Tec homology
  • SH3 Src homology 3
  • SH2 Src homology 2
  • TK or SH1 tyrosine kinase or Src homology 1
  • BTK functions downstream of multiple receptors, include B-cell Receptor (BCR), receptors for growth factors and chemokines, and innate immune receptors.
  • BCR B-cell Receptor
  • BTK initiates a diverse range of cellular processes, such as cell proliferation, survival, differentiation, motility, adhesion, angiogenesis, cytokine production, and antigen presentation, and plays an important role in hematological malignancies and immune disorders (Kurosaki, “Molecular mechanisms in B cell antigen receptor signaling,” Curr OP Imm, 1997, 9(3):309-18).
  • BTK expression levels were shown to set the threshold for malignant transformation; BTK overexpression accelerated leukemia and increased mortality (Kil et al., “Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia,” Am J Blood Res 2013, 3(1):71-83).
  • Ibrutinib also known commercially as IMBRUVICA® was the first BTK inhibitor approved by the United States Food and Drug Administration for treating mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia (WM).
  • MCL mantle cell lymphoma
  • CLL chronic lymphocytic leukemia
  • WM Waldenström's macroglobulinemia
  • BTK inhibitors are not ideal—they inhibit not only BTK, but also various other kinases (such as ETK, EGF, BLK, FGR, HCK, YES, BRK and JAK3, etc.).
  • Known BTK inhibitors also produce a variety of derivatives. These characteristics of known BTK inhibitors lead to a decrease in therapeutic efficacy and an increase in side effects.
  • a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds and the synthesis methods, as well as pharmaceutical compositions comprising the compounds described herein as an active ingredient and the methods of inhibiting BTK activities, are described.
  • the compounds of interest include multi-fluoro-substituted compounds and the corresponding borate, multi-fluoro-substituted phenoxybenzene and the corresponding borate, and the synthesis methods.
  • the polyfluorinated compounds contain at least two fluorine atoms.
  • Ar 1 and Ar 2 are represented by Formulae (III) and (IV), respectively:
  • each of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 and A 10 is C,
  • each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 is selected from H, NO 2 , CF 3 , Cl, or F wherein at least two of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are F,
  • Q is O, S, NR a , and —C( ⁇ O)—, wherein R a is acyl, alkyl, alkenyl or alkynyl;
  • M 1 is unsubstituted or substituted piperidinyl or pyrrolidinyl
  • Y is C( ⁇ O)
  • R 10 is unsubstituted or substituted C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, or an enantiomer, diastereomer, prodrug or pharmaceutically acceptable salt thereof.
  • each H can be optionally substituted with deuterium.
  • Ar 1 is represented by the following formula:
  • Ar 2 is represented by a formula selected from the group consisting of
  • the compound is represented by Formula (IX), or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof:
  • R 1 , R 2 , R 4 and R 5 are F, and R 3 is H. In some embodiments, R 2 is F, and R 1 , R 3 , R 4 and R 5 are H.
  • M 1 is piperidinyl, and R 10 is vinyl, optionally substituted with deuterium. In some embodiments, M 1 is pyrrolidinyl, and R 10 is vinyl, optionally substituted with deuterium.
  • R 10 is unsubstituted vinyl. In some embodiments, R 10 is deuterium-substituted vinyl.
  • the compound is selected from the group consisting of:
  • the compound is represented by the following formula:
  • the compound is represented by the following formula:
  • the compound is represented by the following formula:
  • the compound is represented by the following formula:
  • the compound is represented by the following formula:
  • the compound is represented by the following formula:
  • the compound is represented by the following formula:
  • the compound is represented by the following formula:
  • the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt inhibits Bruton's tyrosine kinase (BTK) with an IC 50 of 0.5 ⁇ M or less.
  • BTK Bruton's tyrosine kinase
  • the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt inhibits BTK with an IC 50 of 0.05 ⁇ M or less.
  • Preferred BTK inhibitory compounds of the present invention include, but not limited to, Compound 11, 12, 13, 15, 16, 17, 18, 20, 21, 23, 33, 45, 47, 61, 72, 73, 74, 75, 87, 91, 94, 95, 98, 99, 100, 106, 116, 120, 121, and 123 (all compounds with IC 50 of less 10 nM) described herein.
  • Another aspect of the invention described herein relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt described herein, and a carrier.
  • Another aspect of the invention described herein relates to a method for inhibiting BTK activity, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt described herein.
  • a further aspect of the invention described herein relates to a method for treating an immune disorder, such as an autoimmune disease, inflammation, and hypersensitity, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt described herein.
  • an immune disorder such as an autoimmune disease, inflammation, and hypersensitity
  • a further aspect of the invention described herein relates to a method for treating a cancer, such as a hematological malignancy (e.g., a B-cell malignancy), comprising administering to a subject in need thereof a therapeutically effective amount of the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt described herein.
  • a cancer such as a hematological malignancy (e.g., a B-cell malignancy)
  • administering to a subject in need thereof a therapeutically effective amount of the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt described herein.
  • FIG. 1 is a graph showing the antitumor effect of multiple doses of Compounds 33 and 45 on tumor volume in a TMD-8 lymphoma xenograft SCID mouse model. “p.o., BID*14”: by mouth twice a day, for 14 days.
  • FIG. 2 is a graph showing the antitumor effect of multiple doses of Compounds 45, 45a, and 45b on tumor volume in a TMD-8 lymphoma xenograft SCID mouse model.
  • the invention relates to the therapeutic methods to treat or inhibit an autoimmune disease, a hypersensitivity disease, an inflammatory disease, and cancer, including administering to a patient in need thereof a therapeutically effective amount of a compound that has a structure of Formula (I) or (II), or an enantiomer, diastereomer, or a pharmaceutically acceptable salt thereof
  • Ar 1 and Ar 2 are independently selected from (III) and (IV):
  • each of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 and A 10 is selected from C and N;
  • each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 is selected from among hydrogen, deuterium, amino, halogen, hydroxy, carbonyl, nitro, cyano, amide, alkyl sulfonamide, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, trifluoromethyl, trifluoromethoxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, and C 3 -C 10 cycloalkyl; wherein each of R 1 -R 9 substituents is optionally substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, amino, hydroxy, carbonyl, nitro, cyano, C 1 -C 6 alkyl, and C 1 -C 6 alkoxyl;
  • each of R 6 , R 7 , R 8 , and R 9 with NH 2 can form a 6-8-membered cycloalkyl ring or heterocyclic ring;
  • Ar 1 is independently selected from benzoaryl and benzo-heteroaryl, wherein said hydrogen is independently replaced with deuterium, halogen, amino, hydroxy, carbonyl, nitro, cyano, C 1 -C 6 alkyl, or C 1 -C 6 alkoxyl;
  • Q is O, S or C( ⁇ O);
  • M 1 is a saturated or unsaturated C 1 -C 8 alkyl, aryl, alkylaryl, arylalkyl, heteroaryl, heteroaryl alkyl, alkyl heteroaryl, cycloalkyl, cycloalkyl alkyl, alkyl cycloalkyl, heterocycloalkyl, heterocycloalkyl alkyl, or alkyl heterocycloalkyl; wherein each of said alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl is optionally substituted with alkyl, cycloalkyl, alkoxyl, epoxyalkyl, amino, cyano, amide or halogen;
  • Y is C( ⁇ O), NR 11 C( ⁇ O) or S( ⁇ O) 2 ;
  • each of R 10 and R 11 is selected from among amino, azacycloalkyl, aryl, heteroaryl, heterocycloalkyl, epoxyalkyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, amide, acyl, guanidyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 1 -C 6 alkoxyl, and C 1 -C 6 oxoalkyl; wherein each pf said amino, amide, acyl, C 2 -C 6 alkenyl, alkyl, alkoxyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, amino, hydroxy, hydroxy alkyl, carbonyl, ester, amide, nitro, cyano, trifluoro
  • the hydrogen atom connected with carbon or nitrogen in the described aryl or hetero-ring can be replaced with alkyl, cycloalkyl, alkoxyl, epoxyalkyl, amino, cyano, amide or halogen.
  • Ar 1 is preferably selected from below formula:
  • Q is preferably O to form Formula (X) and (XI):
  • Ar 2 , M 1 , Y and R 10 are defined as aforementioned.
  • Ar 2 is phenyl or heteroaryl, preferably phenyl, and more preferably
  • M 1 is selected from saturated or unsaturated C 1 -C 8 alkyl, cycloalkyl, cycloalkyl alkyl, alkyl cycloalkyl, heterocycloalkyl, heterocycloalkyl alkyl, and alkyl heterocycloalkyl; wherein each of said alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl is optionally substituted with alkyl, cycloalkyl, alkoxyl, amino, cyano, amide or halogen;
  • M 1 is preferably piperidinyl or pyrrolidinyl
  • Y is C( ⁇ O), NR 11 C( ⁇ O) or S( ⁇ O) 2 , preferably C( ⁇ O) or NR 11 C( ⁇ O), more preferably C( ⁇ O);
  • R 10 is independently selected from among amino, azacycloalkyl, aryl, heteroaryl, heterocycloalkyl, epoxyalkyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, amide, acyl, guanidyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 1 -C 6 alkoxyl, and C 1 -C 6 oxoalkyl; wherein said amino, amide, acyl, C 2 -C 6 alkenyl, alkyl, alkoxyl and cycloalkyl are each optionally substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, amino, hydroxy, hydroxy alkyl, carbonyl, ester, amide, nitro, cyano, trifluoroacetyl, trifluoromethyl
  • R 10 is the most preferably vinyl.
  • alkyl refers to straight or branched alkyl groups containing 1 to 6 carbon atoms, and straight or branched “alkenyl” or “alkynyl” groups containing 2 to 6 carbon atoms, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, vinyl, propenyl, butenyl, pentenyl, hexenyl and isomers thereof.
  • hydroxyl refers to a group with a —OH.
  • halo or halogen refers to fluoro, chloro, bromo or iodo.
  • cycloalkyl refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen. Each ring has 3 to 10 carbon atoms containing one or more double or triple bonds. Examples of cycloalkyl group include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • cycloalkyl also refers to spiral ring system, in which the cycloalkyl rings share one carbon atom.
  • heterocycloalkyl refers to a non-aromatic saturated 5- to 6-member ring that contains one or more heteroatoms each selected from N, O and S (including oxide thereof).
  • the heterocycloalkyl group includes unsaturated ring or fused ring with phenyl, but not includes aza-bridged cyclic hydrocarbon group.
  • heterocycloalkyl group includes, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, indolinyl, tetrahydroquinolyl, tetrahydroisoquinolin and benzoxazinyl, preferably dihydrooxazolyl and tetrahydrofuranyl.
  • azacycloalkyl belonging to “heterocycloalkyl,” refers to a non-aromatic saturated 3- to 8-member ring that contains at least one nitrogen atom and one or more heteroatoms each selected from N, O and S (including oxide thereof), but not includes aza-bridged cyclic hydrocarbon group.
  • azacycloalkyl group includes but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl.
  • aryl refers to an aromatic carbocyclic group, including phenyl, naphthyl and indenyl, preferably with 6 to 10 carbon atoms.
  • heteroaryl refers to a 5- or 6-membered aromatic heterocyclic group having one or more heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atoms, and a sulfur atom.
  • heteroaryl encompasses an aromatic heterocyclic group fused with benzyl group.
  • heteroaryl group examples include, but are not limited to, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, thienyl, furyl, oxadiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, benzthiazolyl, benzoxazolyl, indolyl, indazolyl, quinoxalinyl, quinazolinyl, preferably pyridazinyl, pyridyl, pyrazinyl, pyrazolyl, thiazolyl, pyrazolyl and thio oxazolyl.
  • bridged ring group means refers to “bridged cyclic hydrocarbon group” and “aza-bridged cyclic hydrocarbon group.”
  • bridged cyclic hydrocarbon group is a saturated or unsaturated, bridged bicyclic or polycyclic hydrocarbon group that contains two or three cycloalkyl rings with 3-10 carbon atoms. Unbridged cycloalkyl are not included. Particularly preferred are bridged bicyclic or polycyclic hydrocarbon group containing 4-16 carbon atoms.
  • bridged cyclic hydrocarbon group examples include, but are not limited to, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[4.3.1]decyl, bicyclo[3.3.1]nonyl, bornyl, norbornene group, norbornyl, norbornenyl, 6,6-dimethyl-bicyclo[3.1.1]heptyl, tricyclo butyl and adamantyl, preferably adamantyl or bicyclo [2.2.1] heptyl.
  • nitro refers to a group with a —NO 2 .
  • amine refers to unsubstituted or substituted —NH 2 containing one, two or three groups, for example, alkyl, alkenyl, alkynyl, aryl, etc.
  • cyano refers to a group with a —CN.
  • alkoxy refers to an alkyl group covalently linked to an oxygen atom, which is attached to another molecular moiety.
  • cycloalkyl group include, but are not limited to, methoxyl, ethoxyl, propoxyl, iso-propoxyl, n-butoxyl and tert-butoxyl.
  • acyl refers to —C( ⁇ O)-alkyl, —C( ⁇ O)-alkenyl, —C( ⁇ O)-alkynyl, —C( ⁇ O)-cycloalkyl, —C( ⁇ O)-heterocycloalkyl, —C( ⁇ O)-aryl, —C( ⁇ O)-heteroaryl, carbamoyl, —C( ⁇ O)—C( ⁇ O)-alkyl, —C( ⁇ O)—C( ⁇ O)—NH-alkyl.
  • alkyl,” “cycloalkyl,” “heterocycloalkyl,” “aryl,” and “heteroaryl” herein have the same meaning as stated above.
  • carboxyl refers to a group with a —CO 2 H or a salt thereof.
  • trifloromethyl refers to a group with a —CF 3 .
  • trifluoromethoxy refers to a group with a —OCF 3 .
  • trifluoroacetyl refers to a group with a CF 3 C( ⁇ O)—.
  • alkyl sulfonamide refers to a group with —NR′S( ⁇ O) 2 R.
  • R can be alkyl
  • R′ can be hydrogen or C 1 -C 6 alkyl and the term “alkyl” has the same meaning as defined herein.
  • amide refers to a group with —C( ⁇ O)NHR or —NHC( ⁇ O)R.
  • R can be alkyl, and the term “alkyl” has the same meaning as defined herein.
  • esters refers to a group with —C( ⁇ O)OR.
  • R can be alkyl, and the term “alkyl” has the same meaning as defined herein.
  • alkylaryl or “arylakyl,” each term herein has the same meaning as defined above.
  • salts formed with acid or base including, but not limited to, (a) acid addition salts: inorganic acid (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and other organic acids), and organic acid (e.g., acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, and ascorbic acid); (b) base addition salts, the formation of metal cations, such as zinc, calcium, sodium, and potassium.
  • inorganic acid e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and other organic acids
  • organic acid e.g., acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, and ascorbic acid
  • base addition salts e.g., acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, and ascorbic
  • prodrugs of the compounds described herein refers to a biologically inactive compound that can be metabolized in the body to produce a drug.
  • a prodrug of a BTK inhibitor can be a prodrug at the amino group, for example, an amide, carbamate, or a polyethylene glycol.
  • terapéuticaally effective amount refers to an amount of a drug that is effective in treating the targeted disease as determined by healthcare professionals.
  • Nitrogen atom can form three bonds with other atoms. Any atom other than hydrogen has to be drawn. Hydrogen may or may not be clearly drawn as a typical practice by chemists.
  • R—N means R—NH 2
  • R—NC( ⁇ O)—W means R—NH(C ⁇ O)—W.
  • a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 have the same meaning as defined above.
  • Scheme 1 was designed basing on the literature reported method: 3-fluoro-4-bromo-phenol (or 3-fluoro-4-chloro-phenol) and 3-iodo-fluorobenzene (or 3-fluoro-bromophenyl) under basic conditions was catalyzed by a copper reagent to form 1-bromo-2-fluoro-4-(3-fluorophenoxy)benzene (or 1-chloro-2-fluoro-4-(3-fluorophenoxy)benzene), and then treated with bis(pinacolato)borate with a suitable catalyst (e.g., [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium) to provide the corresponding boronate ester.
  • a suitable catalyst e.g., [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium
  • Fluoro-substituted starting material A1 was treated with substituted phenol B1 to generate intermediate C1 under basic condition (e.g., potassium carbonate) in a suitable solvent (e.g., DMF).
  • Intermediate C1 then reacted with bis(pinacolato)diboron to give intermediate D1 with a suitable catalyst (e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)) under basic condition (e.g., potassium acetate) in a suitable solvent (e.g., 1,4-dioxane).
  • a suitable catalyst e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
  • a suitable solvent e.g., 1,4-dioxane
  • intermediate F1 Iodination of 1H-pyrazolo[3,4-d]pyrimidin-4-amine with NIS formed intermediate F1, followed by Mitsunobu reaction or displacement reaction to furnish intermediate H1.
  • Intermediate H1 was treated with compound D1 above obtained to give intermediate I1 with a suitable catalyst (e.g., Pd-118) under basic condition (e.g., potassium phosphate) in a suitable solvent (e.g., 1,4-dioxane).
  • a suitable catalyst e.g., Pd-118
  • basic condition e.g., potassium phosphate
  • solvent e.g., 1,4-dioxane
  • Intermediate F1 and Boc-protected bromo compound A2 gave intermediate B2 under basic condition (e.g., potassium carbonate or cesium carbonate) in a suitable solvent (e.g., DMF).
  • Intermediate B2 then reacted with heterocyclic borate D1 to give intermediate C2 via Suzuki coupling reaction with a suitable catalyst (e.g., Pd(PPh 3 ) 4 ) under basic condition (e.g., sodium carbonate) in a suitable solvent (e.g., 1,4-dioxane and H 2 O).
  • a suitable catalyst e.g., Pd(PPh 3 ) 4
  • basic condition e.g., sodium carbonate
  • suitable solvent e.g., 1,4-dioxane and H 2 O
  • a suitable catalyst e.g., Pd(PPh 3 ) 4
  • basic condition e.g., sodium carbonate
  • a suitable solvent e.g., 1,4-dioxane and H 2 O
  • De-Boc protection of intermediate C2 gave amine D2 under acidic condition, which was reacted with an electrophilic reagent to form amide E2.
  • Intermediate F1 and Boc-protected bromo compound B4 gave intermediate A4 under basic condition (e.g., potassium carbonate or cesium carbonate) in a suitable solvent (e.g., DMF).
  • Intermediate A4 then reacted with heterocyclic borate D1 to give title compound E2 via Suzuki coupling reaction with a suitable catalyst (e.g., Pd(PPh 3 ) 4 ) under basic condition (e.g., sodium carbonate) in a suitable solvent (e.g., 1,4-dioxane and H 2 O).
  • a suitable catalyst e.g., Pd(PPh 3 ) 4
  • basic condition e.g., sodium carbonate
  • Intermediate D5 then reacted with bis(pinacolato)diboron to give intermediate E5 with a suitable catalyst (e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)) under basic condition (e.g., potassium acetate) in a suitable solvent (e.g., 1,4-dioxane).
  • a suitable catalyst e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
  • basic condition e.g., potassium acetate
  • a suitable solvent e.g., 1,4-dioxane
  • Intermediate A4 then reacted with heterocyclic borate E5 to give title compound F5 via Suzuki coupling reaction with a suitable catalyst (e.g., Pd(PPh 3 ) 4 ) under basic condition (e.g., sodium carbonate) in a suitable solvent (e.g
  • Compound D2 was treated with maleic anhydride provided intermediate A6 under basic condition (e.g., sodium carbonate) in a suitable solvent (e.g., dichloromethane), which was then cyclized to form B6 at suitable temperature (e.g., 100° C.-110° C.) with polyphosphoric acid.
  • suitable solvent e.g., dichloromethane
  • Intermediate D7 then reacted with bis(pinacolato)diboron to give intermediate E7 with a suitable catalyst (e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)) under basic condition (e.g., potassium acetate) in a suitable solvent (e.g., 1,4-dioxane).
  • a suitable catalyst e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
  • basic condition e.g., potassium acetate
  • suitable solvent e.g., 1,4-dioxane
  • Intermediate H1 was treated with compound E7 above obtained to give intermediate F7 with a suitable catalyst (e.g., Pd-118) under basic condition (e.g., potassium phosphate) in a suitable solvent (e.g., 1,4-dioxane).
  • the invention provides a compound of Formula (I)-(XIII), enantiomers thereof, diastereomers thereof, or pharmaceutically acceptable salts thereof.
  • a compound of Formula (I)-(XIII) comprises one or more stable isotopes or radio isotopes, wherein the autoimmune disease includes, but not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O and so on.
  • the present invention first introduces 2 H, isotope of 1 H, to BTK inhibitor.
  • the invention provides the synthetic methods of a compound of Formula (I)-(XIII), enantiomers thereof and diastereomers thereof.
  • TK toxicokinetic
  • Compound 45 has low toxicity, excellent pharmacokinetics, and superior bioavailability when compared to ibrutinib.
  • BTK inhibitory compounds described herein including those with Formula (I)-(XIII) can be provided as active ingredients in the pharmaceutical compositions of the invention for use in regulating the activity of BTK, and treating or preventing diseases associated with the activity of BTK, wherein inhibition of BTK is beneficial.
  • autoimmune diseases such as chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, chronic ulcerative colitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, pernicious anemia associated with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple cerebrospinal sclerosis, acute idiopathic neuritis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, systemic vasculitis, scleroderma, pemphigus, mixed connective tissue disease, multiple sclerosis, autoimmune hemolytic anemia, and autoimmune thyroid disease; (2) hypersensitivity diseases, such as serum sickness, asthma, allergic rhinitis, and drug allergy; and (3) inflammatory diseases, such as keratitis, chronic lymphocytic thyroiditis,
  • the present compounds and compositions can also be used to treat a variety of cancer, including hematological malignancies various such as B-cell malignancies, e.g., small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Richter's syndrome, diffuse large B-cell lymphoma (DLBCL), Waldenström Macroglobulinemia (WM), follicular lymphoma (FL), mantle cell lymphoma (MCL)), Hodgkin lymphoma, non-Hodgkin lymphoma, and T cell lymphomas.
  • B-cell malignancies e.g., small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Richter's syndrome, diffuse large B-cell lympho
  • Other diseases which would benefit from inhibition of BTK activity, include but not limited to: brain tumors, bladder cancer, stomach cancer, ovarian cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, kidney cancer, esophageal cancer, adenocarcinoma of the previous example, thyroid cancer, bone cancer, skin cancer, colon cancer, female reproductive tract tumors, lymphomas, multiple myeloma (MM), testicular cancer and so on.
  • brain tumors bladder cancer, stomach cancer, ovarian cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, kidney cancer, esophageal cancer, adenocarcinoma of the previous example, thyroid cancer, bone cancer, skin cancer, colon cancer, female reproductive tract tumors, lymphomas, multiple myeloma (MM), testicular cancer and so on.
  • MM multiple myeloma
  • the method herein includes administering to a patient in need thereof a therapeutically effective amount of a compound described herein.
  • the BTK inhibitory compounds of the invention can be used alone in a pharmaceutical formulation or with one or more additional drugs in a pharmaceutical combination, wherein the pharmaceutical formulation comprising BTK inhibitors and the additional drugs may have the same or different administration route, and the same or different administration time.
  • the additional drugs herein include (but are not limited to) other tyrosine kinase inhibitors (e.g., Axitinib, Dasatinib, Icotinib), topoisomerase inhibitors (e.g., topotecan), protein kinase C inhibitors (e.g., AEB-071), sphingosine-1-phosphate receptor agonist (e.g., fingolimod, KRP-203), anti-T cell immunoglobulin (e.g., AtGam), anti-IL-2 receptor antibody (e.g., daclizumab), amides (CTX), ifosfamide (IFO), adriamycin (ADM), daunorubicin (DNR), vincristine (VCR), vinblastine (VBL), etoposide (VP16), vermeer (Vumon), carboplatin (CBP) and methotrexate (MTX) cyclosporin A, tacroli
  • Carriers, excipients and other additives commonly used for pharmaceutical preparations may be used to prepare pharmaceutical compositions containing one or two or more compounds of formula (I)-(XIII) or pharmaceutically acceptable salts thereof as active ingredients.
  • the administration forms may be oral dosage forms, such as tablets, pills, capsules, granules, powders, emulsions, syrups, suspensions, liquid preparations, or non-oral dosage forms, such as intravenous injection or intramuscular injection, suppository, subcutaneous agent, transdermal agent, nasal agent, inhalation. Symptoms, age, weight, sex, and other relevant medical information of the individual patient should be considered in order to properly determine the dose of a compound. Generally speaking, in the case of oral administration, daily doses for adult patients of the compound is about 0.001 mg/kg to 100 mg/kg, a single dose or divided into 2 to 4 times daily.
  • daily doses for adult patients are 0.0001 mg/kg to 10 mg/kg, once to more times daily. Further, in the case of using the inhalant administration, generally speaking, daily doses for adult patients is 0.0001 mg/kg to 1 mg/kg, once to more times daily.
  • solid compositions for oral administration may be tablets, powders, granules and the like.
  • one or more active substance with at least one inert excipient e.g., lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, poly vinyl pyrrolidone, magnesium aluminum silicate, etc.
  • the composition may contain inert additives such as lubricants (e.g., magnesium stearate), disintegrating agents (e.g., sodium carboxymethyl starch) and dissolution aids.
  • lubricants e.g., magnesium stearate
  • disintegrating agents e.g., sodium carboxymethyl starch
  • tablets or pills may be coated with sugar coating or a gastric or enteric coating agent.
  • the liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, and commonly used inert diluent (e.g., purified water, ethanol).
  • inert diluent e.g., purified water, ethanol
  • the composition may also contain additives such as solubilizing agents, wetting agents, suspending agents, and sweetener, flavoring agents, flavoring agents and preservatives.
  • Injections for parenteral administration include sterile aqueous or non-aqueous liquid preparations, suspensions, emulsions.
  • Diluent aqueous solution can be used (for example) include distilled water for injection and physiological saline.
  • Non-aqueous diluent solution can be used (e.g.) include propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), alcohols (e.g., ethanol) and polysorbate 80.
  • Such compositions may further contain isotonic agents, such as preservatives, wetting agents, emulsifying agents, dispersing agents, stabilizing agents, dissolving aids and the like additives.
  • compositions may be employed by filtration through a bacteria retaining filter, adding bactericides or irradiation with light to a method of sterilizing the composition.
  • these compositions may be made sterile solid compositions before use and then sterile water or a sterile solvent for injection prior to use dissolved or suspended.
  • Transmucosal agents such as inhalations and nasal agents and the like, can be solid, liquid, or semi-solid state of use, and can be in accordance with conventionally known methods used to prepare these transmucosal agent.
  • an excipient may be added as needed (e.g., lactose and starch), pH adjusting agent, a preservative IJ, surfactants, lubricants IJ, stabilizing and thickening agents and the like.
  • metered dose inhaler devices may be used a known device or sprayer, the compound alone or as a mixture after the powder formulation to be administered.
  • the compound may be combined with a pharmaceutically acceptable carrier, administered as a solution or suspension.
  • a pharmaceutically acceptable carrier administered as a solution or suspension.
  • the dry powder inhaler or the like may be used for a single dose or multiple doses, and can use a dry powder or a powder-containing capsule.
  • a pressurized aerosol spray can also be used in the form to be administered by the use of a suitable propellant (e.g., chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide).
  • a suitable propellant e.g., chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide.
  • Triethylamine (15 g, 150 mmol, 3.0 eq.) and methanesulfonyl chloride (6.3 g, 55 mmol, 1.1 eq.) were sequentially added dropwise to a solution of tert-butyl 3-hydroxypiperidine-1-carboxylate (10.0 g, 50 mmol, 1.0 eq.) in dichloromethane (100 mL) at 0° C.
  • the reaction was stirred at 20° C. for 1 hour, quenched with saturated NaHCO 3 (100 mL), and then extracted with methylene chloride (200 mL ⁇ 3). The organic phase was dried over anhydrous sodium sulfate, and concentrated to give the title compound (13 g, yield: 95%).
  • Triethylamine (3.2 g, 31.5 mmol, 3.0 eq.) and acrylic chloride (950 mg, 10.5 mmol, 1.0 eq.) were subsequently added to a solution of 3-iodo-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride (4 g, 10.5 mmol, 1.0 eq.) in dichloromethane (50 mL) at 0° C.
  • the reaction mixture was stirred at 0° C. for 1 hour, and quenched with saturated sodium bicarbonate solution (30 mL).
  • the aqueous phase was extracted with dichloromethane (50 mL ⁇ 2).
  • Tetrapropylammonium perruthenate 80 mg, 0.22 mmol, 0.15 eq.
  • N-methyl morpholine oxide 346 mg, 2.96 mmol, 2.0 eq.
  • 4A molecular sieves 300 mg
  • the reaction mixture was stirred at room temperature for 2 hours, and then concentrated.
  • the reaction mixture was stirred at 85° C. for 30 minutes under nitrogen atmosphere with microwave irradiation.
  • the reaction solution was diluted with water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated to give the crude product, which was purified by thin layer chromatography (developer: ethyl acetate) to give the title compound (70 mg, yield: 12%).
  • the reaction mixture was stirred at 85° C. for 30 minutes under nitrogen atmosphere with microwave irradiation.
  • the reaction solution was diluted with water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated to give the crude product, which was purified by HPLC (C18 reverse phase column, mobile phase: acetonitrile/water, gradient 10%-100% (volume ratio)) to give the title compound (42 mg, yield: 10%).
  • Tetrapropylammonium perruthenate 80 mg, 0.22 mmol, 0.15 eq.
  • N-methyl morpholine oxide 346 mg, 2.96 mmol, 2.0 eq.
  • 4A molecular sieves 300 mg
  • the reaction mixture was stirred at room temperature for 2 hours, and then concentrated.
  • the reaction mixture was stirred at 85° C. for 30 minutes under nitrogen atmosphere with microwave irradiation.
  • the reaction solution was diluted with water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated to give the crude product, which was purified by HPLC (C18 reverse phase column, mobile phase: acetonitrile/water/0.5% HCl, gradient 10%-100% (volume ratio)) to give the title compound hydrochloride (10 mg, yield: 4%).
  • the reaction mixture was stirred at 85° C. for 30 minutes under nitrogen atmosphere with microwave irradiation.
  • the reaction solution was diluted with water (20 mL), and then extracted with ethyl acetate (20 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated to give the crude product, which was purified by by HPLC (C18 reverse phase column, mobile phase: acetonitrile/water/0.5% HCl, gradient 10%-100% (volume ratio)) to give the title compound hydrochloride (70 mg, yield: 6%).
  • Tetrapropylammonium perruthenate 350 mg, 1.0 mmol, 0.15 eq.
  • N-methyl morpholine oxide (1.56 g, 13.4 mmol, 2.0 eq.
  • 4A molecular sieves 1.0 g were added to a solution of (4-bromo-3-fluorophenyl)(3-fluorophenyl)methanol (2.0 g, 6.69 mmol, 1.0 eq.) in dichloromethane (20 mL).
  • the reaction mixture was stirred at room temperature for 2 hours, and then concentrated.
  • the reaction mixture was stirred at 85° C. for 30 minutes under nitrogen atmosphere with microwave irradiation.
  • the reaction solution was diluted with water (50 mL), and then extracted with ethyl acetate (50 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated to give the crude product, which was purified by by HPLC (C18 reverse phase column, mobile phase: acetonitrile/water/0.5% HCl, gradient 10%-100% (volume ratio)) to give the title compound hydrochloride (150 mg, yield: 4%).
  • the reaction mixture was stirred at 85° C. for 30 minutes under nitrogen atmosphere with microwave irradiation.
  • the reaction solution was diluted with water (50 mL), and then extracted with ethyl acetate (50 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered.
  • 5-methylisoxazole-4-carboxylic acid (15 mg, 0.11 mmol, 1.1 eq.), HATU (60 mg, 0.15 mmol, 1.5 eq.) and DIPEA (38 mg, 0.3 mmol, 3.0 eq.) were added to a solution of (4-(4-amino-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-fluorophenyl)(3-fluorophenyl)methanone (45 mg, 0.1 mmol, 1.0 eq.) in dichloromethane (10 mL).
  • Triethylamine (17 mg, 0.16 mmol, 3.0 eq.) was added to a solution of (3-(4-amino-3-(2-fluoro-4-(3-fluorobenzoyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)(5-methylisoxazol-4-yl)methanone (30 mg, 0.055 mmol, 1.0 eq.) in tetrahydrofuran (10 mL). The reaction was stirred at room temperature for 12 hours and concentrated to give the title compound (26 mg, yield: 83%).
  • 2-chloroethanesulfonyl chloride (16 mg, 0.1 mmol, 1.0 eq.) and triethylamine (50 mg, 0.5 mmol, 5.0 eq.) were added to a solution of (4-(4-amino-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-fluorophenyl)(3-fluorophenyl)methanone (45 mg, 0.1 mmol, 1.0 eq.) in dichloromethane (10 mL).
  • Potassium oxirane-2-carboxylate (19 mg, 0.15 mmol, 1.0 eq.), PyBrop (84 mg, 0.18 mmol, 1.2 eq.) and DIPEA (38 mg, 0.3 mmol, 2.0 eq.) were added to a solution of (4-(4-amino-1-(piperidin-3-yl)-1H-pyrazol o[3,4-d]pyrimidin-3-yl)-3-fluorophenyl)(3-fluorophenyl)methanone (65 mg, 0.15 mmol, 1.0 eq.) in DMF (2 mL). The reaction was stirred 90° C. for 12 hours.
  • reaction mixture was stirred at 60° C. for 14 minutes under nitrogen atmosphere. After cooled to room temperature, the reaction was diluted with ice-water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product, which was purified by thin layer chromatography (developer: ethyl acetate) to give the title compound (150 mg, yield: 62%).
  • 2-fluoro-nitrobenzene (20 mg, 0.14 mmol, 1.2 eq.) and potassium carbonate (32 mg, 0.233 mmol, 2.0 eq.) were added to a solution of tert-butyl 3-(4-amino-3-(2-fluoro-4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate (50 mg, 0.117 mmol, 1.0 eq.) in DMF (2 mL). The reaction mixture was stirred at 100° C. for 14 hours. After cooling to room temperature, the mixture was filtered, and the filter cake washed with ethyl acetate.
  • the reaction mixture was stirred at 60° C. for 12 hours under nitrogen atmosphere.
  • the reaction solution was poured into ice-water (300 mL), and then extracted with ethyl acetate (100 mL ⁇ 4).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated to give the crude product, which was purified by silica gel column chromatography (eluent: ethyl acetate) to give the title compound (6.8 g, yield: 69%).
  • Triethylamine (887 mg, 8.7 mmol, 3.0 eq.) and acrylic chloride (0.26 g, 2.9 mmol, 1.0 eq.) were added subsequently to a solution of 3-(2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.5 g, 2.9 mmol, 1.0 eq.) in dichloromethane (10 mL). The reaction mixture was stirred at 0° C.
  • 1,3-difluoro-2-nitrobenzene 222.8 mg, 1.4 mmol, 3.0 eq.
  • potassium carbonate 96.8 mg, 0.7 mmol, 1.5 eq.
  • a solution of tert-butyl 3-(4-amino-3-(2-fluoro-4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 200 mg, 0.467 mmol, 1.0 eq.
  • the reaction mixture was stirred at 60° C. for 12 hours.
  • Triethylamine 45 mg, 0.45 mmol, 3.0 eq.
  • acrylic chloride 13 mg, 0.15 mmol, 1.0 eq.
  • 3-(2-fluoro-4-(3-fluoro-2-nitrophenoxy)phenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 75 mg, 0.15 mmol, 1.0 eq.
  • dichloromethane 2 mL
  • Chloride ammonium 28 g, 525 mmol, 2.5 eq.
  • iron powder 58.8 g, 1.05 mol, 5.0 eq.
  • the reaction solution was refluxed under nitrogen for 12 hours. After cooled to room temperature, the reaction was filtered through celite.
  • Triethylamine (7 g, 70 mmol, 3.0 eq.) and methanesulfonyl chloride (2.9 g, 25.5 mmol, 1.1 eq.) were subsequently added to a solution of tert-butyl (1r,4r)-4-hydroxycyclohexylcarbamate (5.0 g, 23.2 mmol, 1.0 eq.) in dichloromethane (100 mL) at 0° C.
  • the reaction was stirred at 20° C. for 1 hour, quenched with saturated NaHCO 3 (100 mL), and then extracted with dichloromethane (200 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (6.0 g, yield: 88%).
  • Triethylamine (1.9 g, 19 mmol, 3.0 eq.) and acrylic chloride (570 mg, 6.3 mmol, 1.0 eq.) were subsequently added to a solution of 1-((1s,4s)-4-aminocyclohexyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (2.5 g, 6.3 mmol, 1.0 eq.) in dichloromethane (50 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (30 mL). The aqueous phase was extracted with dichloromethane (50 mL ⁇ 2).
  • Triethylamine (1.4 g, 14.0 mmol, 3.0 eq.) and methanesulfonyl chloride (0.8 g, 7.0 mmol, 1.5 eq.) were added sequentially to a solution of tert-butyl (1s,4s)-4-hydroxycyclohexylcarbamate (1.0 g, 4.6 mmol, 1.0 eq.) in dichloromethane (30 mL) at 0° C.
  • the reaction was stirred at 0° C. for 1 hour, quenched with water (5 mL), washed with water (30 mL ⁇ 2) and brine (30 mL).
  • the organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (860 mg, yield: 64%).
  • Triethylamine 40 mg, 0.39 mmol, 3.0 eq.
  • acrylic chloride 23 mg, 0.26 mmol, 2.0 eq.
  • 1-((1r,4r)-4-aminocyclohexyl)-3-(2-fluoro-4-(3-fluorophenoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 61.5 mg, 0.13 mmol, 1.0 eq.
  • dichloromethane 5 mL
  • the reaction mixture was stirred at 0° C.
  • Triethylamine (35 g, 346 mmol, 2.1 eq.) and methanesulfonyl chloride (36.6 g, 321 mmol, 1.9 eq.) were added subsequently to a solution of tert-butyl 3-hydroxypyrrolidine-1-carboxylate (30.0 g, 163 mmol, 1.0 eq.) in dichloromethane (200 mL) at 0° C.
  • the reaction was stirred at 0° C. for 3 hours, quenched with water (20 mL), washed with water (100 mL ⁇ 2) and brine (100 mL).
  • the organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (45.6 g, yield: 100%).
  • Triethylamine (4.8 g, 48 mmol, 3.0 eq.) and acrylic chloride (750 mg, 8.0 mmol, 0.5 eq.) were subsequently added to a solution of 3-iodo-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (5.3 g, 16 mmol, 1.0 eq.) in dichloromethane (50 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (10 mL), washed with water (30 mL ⁇ 2) and brine (30 mL).
  • Triethylamine (3.14 g, 31.05 mmol, 2.5 eq.) and methanesulfonyl chloride (3.5 g, 24.84 mmol, 1.2 eq.) were added sequentially to a solution of tert-butyl (1s,3r)-3-hydroxycyclopentylcarbamate (2.5 g, 12.42 mmol, 1.0 eq.) in dichloromethane (25 mL) at 0° C.
  • the reaction was stirred at room temperature for 14 hours, quenched with water (20 mL), and then extracted with dichloromethane (25 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (2.5 g, yield: 72%).
  • Triethylamine (170 mg, 1.7 mmol, 3.0 eq.) and acrylic chloride (51 mg, 0.56 mmol, 1.1 eq.) were added subsequently to a solution of 1-((1s,3s)-3-aminocyclopentyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (215 mg, 0.56 mmol, 1.0 eq.) in dichloromethane (15 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (10 mL). The organic layer was extracted with dichloromethane (5 mL ⁇ 2).
  • N-((1s,3s)-3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclopentyl)acrylamide (70 mg, 0.175 mmol, 1.0 eq.), 2-(2-fluoro-4-(3-fluorophenoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (116.8 mg, 0.35 mmol, 1.1 eq.), sodium carbonate (93 mg, 0.875 mmol, 3.0 eq.) and Pd(PPh 3 ) 4 (20 mg, 0.017 mmol, 0.1 eq.) were dissolved in 1,4-dioxane/water (10 mL, 1/1, v/v).
  • reaction solution was stirred at 85° C. for 40 minutes under nitrogen atmosphere with microwave irradiation. After cooling to room temperature, the reaction mixture was diluted with water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by HPLC (C18 reverse phase column, mobile phase: acetonitrile/water/0.5% HCl, gradient: 10% to 100% (volume ratio)) to give Compound 16 hydrochloride (11 mg, yield: 5%) and Compound 17 hydrochloride (3.8 mg, yield: 2%).
  • HPLC C18 reverse phase column, mobile phase: acetonitrile/water/0.5% HCl, gradient: 10% to 100% (volume ratio)
  • reaction solution was stirred at 85° C. for 40 minutes under nitrogen atmosphere with microwave irradiation. After cooling to room temperature, the reaction mixture was diluted with water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by thin layer chromatography (developer: ethyl acetate) to give the title compound (25 mg, yield: 4.3%).
  • N-(2-(3-fluoro-4-bromophenoxy)phenyl)methanesulfonamide (1.0 g, 2.78 mmol, 1.0 eq.), bis(pinacolato)diboron (0.85 g, 3.33 mmol, 1.2 eq.), potassium acetate (0.95 g, 9.72 mmol, 3.5 eq.) and (1,1′-bis(diphenylphosphino)ferrocene)dichloropalladium (121 mg, 0.16 mmol, 0.06 eq.) were dissolved in 1,4-dioxane (10 mL). The resulting mixture was stirred at 80° C. under nitrogen atmosphere for 12 hours. The reaction mixture was filtered through celite. The filtrate was concentrated to give the crude product (1.13 g, yield: 100%), which was used directly in the next step.
  • reaction solution was stirred at 85° C. for 40 minutes under nitrogen atmosphere with microwave irradiation. After cooling to room temperature, the reaction mixture was diluted with water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product, which was purified by HPLC (C18 reverse phase column, mobile phase: acetonitrile/water/7 ⁇ NH 4 HCO 3 , gradient: 10% to 100% (volume ratio)) to give the title compound (5 mg, yield: 4%).
  • Triethylamine (2.02 g, 20 mmol, 6.0 eq.) and methylsulfonyl chloride (1.2 g, 10.6 mmol, 3.0 eq.) were subsequently added to a solution of 3-(4-bromo-3-fluorophenoxy)aniline (1.0 g, 3.54 mmol, 1.0 eq.) in dichloromethane (25 mL) at 0° C.
  • N-(3-(4-bromo-3-fluorophenoxy)phenyl)methanesulfonamide (640 mg, 1.78 mmol, 1.0 eq.), bis(pinacolato)diboron (496 mg, 1.95 mmol, 1.1 eq.), potassium acetate (523 mg, 5.33 mmol, 3.0 eq.) and (1,1′-bis(diphenylphosphino)ferrocene)dichloropalladium (126 mg, 0.178 mmol, 0.1 eq.) were dissolved in 1,4-dioxane (10 mL). The resulting mixture was stirred at 80° C. under nitrogen atmosphere for 12 hours. The reaction mixture was filtered through celite. The filtrate was concentrated to give the crude product (0.8 g, yield: 100%), which was used directly in the next step.
  • reaction solution was stirred at 85° C. for 40 minutes under nitrogen atmosphere with microwave irradiation. After cooling to room temperature, the reaction mixture was diluted with water (10 mL), and then extracted with ethyl acetate (10 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by HPLC (C18 reverse phase column, mobile phase: acetonitrile/water/0.5% HCl, gradient: 10% to 100% (volume ratio)) to give the title compound hydrochloride (16 mg, yield: 22%).
  • HPLC C18 reverse phase column, mobile phase: acetonitrile/water/0.5% HCl, gradient: 10% to 100% (volume ratio)
  • 1,2,3,4-fluorobenzene (20 mg, 0.13 mmol, 1.0 eq.) and potassium carbonate (35 mg, 0.26 mmol, 2.0 eq.) were added to a solution of 1-(3-(4-amino-3-(2-fluoro-4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (50 mg, 0.13 mmol, 1.0 eq.) in DMF (5 mL). The reaction was stirred at 100° C. and for 4 hours.
  • Triethylamine (7.16 g, 70.7 mmol, 3.0 eq.) and methanesulfonyl chloride (5.4 g, 45 mmol, 2.05 eq.) were subsequently added to a solution of tert-butyl (1r,4r)-4-hydroxycyclohexylcarbamate (5.08 g, 23.6 mmol, 1.0 eq.) in dichloromethane (50 mL) at 0° C.
  • the reaction was stirred at room temperature for 14 hours, quenched with water (60 mL), and then extracted with dichloromethane (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (6.0 g, yield: 87%).
  • Triethylamine (1.03 g, 10.19 mmol, 3.0 eq.) and acrylic chloride (307 mg, 3.4 mmol, 1.0 eq.) were subsequently added to a solution of (1r,4r)-4-aminocyclohexyl methanesulfonate (780 mg, 3.4 mmol, 1.0 eq.) in dichloromethane (15 mL) at 0° C.
  • the reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (10 mL).
  • the aqueous phase was extracted with dichloromethane (5 mL ⁇ 2).
  • the combined organic layers were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated to give the title compound (780 mg, yield: 93%).
  • Triethylamine (4.8 g, 48 mmol, 3.0 eq.) and methanesulfonyl chloride (3.7 g, 32 mmol, 2.0 eq.) were subsequently added to a solution of tert-butyl 3-hydroxypyrrolidine-1-carboxylate (3.0 g, 16 mmol, 1.0 eq.) in dichloromethane (50 mL) at 0° C.
  • the reaction was stirred at room temperature for 2 hours, quenched with water (60 mL), and then extracted with dichloromethane (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (4.0 g, yield: 95%).
  • Triethylamine (4.5 g, 45 mmol, 3.0 eq.) and acrylic chloride (1.01 g, 12 mmol, 0.8 eq.) were added subsequently to a solution of pyrrolidin-3-yl methanesulfonate (2.5 g, 15 mmol, 1.0 eq.) in dichloromethane (305 mL) at 0° C.
  • the reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (10 mL).
  • the aqueous phase was extracted with dichloromethane (5 mL ⁇ 2).
  • the combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (2.5 g, yield: 83%).
  • N-((1r,3r)-3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclopentyl)acrylamide (70 mg, 0.17 mmol, 1.0 eq.), 2-(2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (135 mg, 0.35 mmol, 2.0 eq.), sodium carbonate (56 mg, 0.52 mmol, 3.0 eq.) and Pd(PPh 3 ) 4 (20 mg, 0.0175 mmol, 0.1 eq) was dissolved in 1,4-dioxane (10 mL, 1/1, v/v) in.
  • Triethylamine (180 mg, 1.79 mmol, 2.0 eq.) and methanesulfonyl chloride (204 mg, 1.79 mmol, 2.0 eq.) were subsequently added to a solution of tert-butyl (1s,3s)-3-hydroxycyclopentylcarbamate (180 mg, 0.895 mmol, 1.0 eq.) in dichloromethane (3 mL) at 0° C.
  • the reaction was stirred at 0° C. for 1 hour, quenched with water (5 mL).
  • the aqueous layer was washed with dichloromethane (5 mL ⁇ 2).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (200 mg, yield: 80%).
  • Triethylamine (3.0 mg, 0.03 mmol, 2.0 eq.) and acryloyl chloride (1.5 mg, 0.017 mmol, 1.1 eq.) were added subsequently to a solution of 1-((1r,3s)-3-aminocyclopentyl)-3-(2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (8 mg, 0.015 mmol, 1.0 eq.) in dichloromethane (1 mL) at 0° C. The reaction mixture was stirred at 0° C.
  • Triethylamine (0.98 g, 9.75 mmol, 3.0 eq.) and methanesulfonyl chloride (0.74 g, 6.5 mmol, 2.0 eq.) were subsequently added to a solution of tert-butyl (3-hydroxycyclopentyl)methylcarbamate (0.7 g, 3.25 mmol, 1.0 eq.) in dichloromethane (25 mL) at 0° C.
  • the reaction was stirred at 20° C. for 14 hours, quenched with saturated NaHCO 3 (20 mL), then extracted with dichloromethane (20 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate, and concentrated to give the title compound (0.76 g, yield: 80%).
  • Triethylamine 530 mg, 5.3 mmol, 2.0 eq.
  • acryloyl chloride 280 mg, 3.2 mmol, 1.2 eq.
  • dichloromethane 15 mL
  • the reaction mixture was stirred at 0° C. for 2 hour, and then quenched with saturated NaHCO 3 (10 mL).
  • the aqueous layer was extracted with dichloromethane (10 mL ⁇ 2). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (400 mg, yield: 60%).
  • Triethylamine (3.02 g, 30.0 mmol, 3.0 eq.) and methanesulfonyl chloride (2.28 g, 20 mmol, 2.0 eq.) were subsequently added to a solution of tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (0.7 g, 3.25 mmol, 1.0 eq.) in dichloromethane (20 mL) at 0° C.
  • the reaction was stirred at 0° C. for 1 hours, quenched with water (20 mL), then extracted with dichloromethane (10 mL ⁇ 2).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (2.5 g, yield: 90%).
  • Triethylamine (2.7 g, 26.7 mmol, 3.0 eq.) and acryloyl chloride (0.97 g, 10.7 mmol, 1.1 eq.) were subsequently added to a solution of pyrrolidin-3-ylmethyl methanesulfonate (1.9 g, 8.9 mmol, 1.0 eq.) in dichloromethane (30 mL) at 0° C.
  • the reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (10 mL).
  • the aqueous layer was extracted with dichloromethane (10 mL ⁇ 3).
  • the combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (1.5 g, yield: 65%).
  • Triethylamine (3.76 g, 37.2 mmol, 2.0 eq.) and methanesulfonyl chloride (3.19 g, 27.9 mmol, 1.5 eq.) were subsequently added to a solution of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (4.0 g, 18.6 mmol, 1.0 eq.) in dichloromethane (25 mL) at 0° C.
  • the reaction was stirred at 20° C. for 14 hours, quenched with water (20 mL), then extracted with dichloromethane (50 mL ⁇ 3).
  • the combined organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (4.5 g, yield: 83%).
  • Triethylamine (4.63 g, 45.7 mmol, 3.0 eq.) and acryloyl chloride (1.38 g, 15.2 mmol, 1.0 eq.) were subsequently added to a solution of piperidin-4-ylmethyl methanesulfonate (3.5 g, 15.2 mmol, 1.0 eq.) in dichloromethane (15 mL) at 0° C.
  • the reaction mixture was stirred at 0° C. for 2 hour, and then quenched with water (60 mL).
  • the aqueous layer was extracted with dichloromethane (100 mL ⁇ 3).
  • the combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (2.5 g, yield: 66%).
  • Triethylamine (1.9 g, 18.6 mmol, 2.0 eq.) and methanesulfonyl chloride (2.12 g, 18.6 mmol, 2.0 eq.) were subsequently added to a solution of tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate (2.0 g, 18.6 mmol, 1.0 eq.) in dichloromethane (20 mL) at 0° C.
  • the reaction was stirred at 0° C. for 1 hours, quenched with water (20 mL), then extracted with dichloromethane (10 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate, and concentrated to give the title compound (2.5 g, yield: 92%).
  • Triethylamine (1.67 g, 16.6 mmol, 2.0 eq.) and acryloyl chloride (0.82 g, 9.1 mmol, 1.1 eq.) were subsequently added to a solution of piperidin-3-ylmethyl methanesulfonate (1.93 g, 8.3 mmol, 1.0 eq.) in dichloromethane (30 mL) at 0° C.
  • the reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (10 mL).
  • the aqueous layer was extracted with dichloromethane (10 mL ⁇ 3).
  • the combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (1.5 g, yield: 71%).
  • Triethylamine (3.8 g, 30 mmol, 2.0 eq.) and ethanol (754 mg, 16.37 mmol, 2.0 eq.) were subsequently added dropwise solution of 3-oxocyclopentanecarbonyl chloride (1.28 g, 8.2 mmol, 1.0 eq.) in dichloromethane (20 mL) at 0° C.
  • the reaction was stirred at room temperature for 2 hours, quenched with water (20 mL).
  • the aqueous phase was extracted with methylene chloride (10 mL ⁇ 2).
  • 2,4-dimethoxybenzyl amine (556 mg, 4.66 mmol, 1.0 eq.), sodium triacetoxyborohydride (446 mg, 3.32 mmol, 1.4 eq.) and acetic acid (200 mg, 3.32 mmol, 1.0 eq.) were added to a solution of ethyl 3-oxocyclopentanecarboxylate (520 mg, 3.32 mmol, 1.0 eq.) in tetrahydrofuran (5 mL) at 0° C. The reaction was stirred at room temperature for 14 hours, quenched with saturated NaHCO 3 (10 mL). The aqueous phase was extracted with ethyl acetate (10 mL ⁇ 2).
  • Triethylamine (171 mg, 1.7 mmol, 3.0 eq.) and methanesulfonyl chloride (129 mg, 1.13 mmol, 2.0 eq.) were subsequently added to a solution of (3-(2,4-dimethoxybenzylamino)cyclopentyl)methanol (150 mg, 0.566 mmol, 1.0 eq.) in dichloromethane (20 mL) at 0° C. The reaction was stirred at room temperature for 14 hours, quenched with water (10 mL), then extracted with dichloromethane (10 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate, and concentrated to give the title compound (194 mg, yield: 100%).
  • Triethylamine (220 mg, 2.18 mmol, 3.0 eq.) and acryloyl chloride (79 mg, 0.873 mmol, 1.2 eq.) were subsequently added to a solution of (3-(2,4-dimethoxybenzylamino)cyclopentyl)methyl methanesulfonate (250 mg, 0.727 mmol, 1.0 eq.) in dichloromethane (10 mL) at 0° C.
  • the reaction mixture was stirred at 0° C. for 1 hour, and then quenched with saturated NaHCO 3 (10 mL).
  • the aqueous layer was extracted with dichloromethane (10 mL ⁇ 3).
  • the combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the title compound (200 mg, yield: 69%).
  • N-(3-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)cyclopentyl)acrylamide (15 mg, 0.036 mmol, 1.0 eq.), 2-(2-fluoro-4-(2,3,5,6-tetrafluorophenoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (21 mg, 0.054 mmol, 1.5 eq.), potassium carbonate (17 mg, 0.127 mmol, 3.0 eq.) and Pd(PPh 3 ) 4 (4 mg, 0.0036 mmol, 0.1 eq.) were dissolved in 1,4-dioxane (8 mL, 3/1, v/v).
  • Triethylamine (9.4 g, 92 mmol, 2.0 eq.) and methanesulfonyl chloride (10.5 g, 92 mmol, 2.0 eq.) were subsequently added to a solution of tert-butyl 4-hydroxycyclohexylcarbamate (10 g, 46 mmol, 1.0 eq.) in dichloromethane (100 mL) at 0° C.
  • the reaction was stirred at room temperature for 14 hours, quenched with saturated NaHCO 3 (50 mL).
  • the aqueous layer was extracted with dichloromethane (30 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate, and concentrated to give the title compound (11 g, yield: 80%).
  • the reaction was stirred at 80° C. for 12 hours under nitrogen atmosphere.
  • the reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (10 mL ⁇ 3).
US15/075,033 2014-04-29 2016-03-18 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors Active US9532990B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/356,014 US9861636B2 (en) 2014-04-29 2016-11-18 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
US15/820,614 US10300066B2 (en) 2014-04-29 2017-11-22 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410175783 2014-04-29
CN201410175783.7 2014-04-29
CN201410175783.7A CN105017256A (zh) 2014-04-29 2014-04-29 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
PCT/CN2015/000290 WO2015165279A1 (zh) 2014-04-29 2015-04-27 多氟化合物作为布鲁顿酪氨酸激酶抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/000290 Continuation-In-Part WO2015165279A1 (zh) 2014-04-29 2015-04-27 多氟化合物作为布鲁顿酪氨酸激酶抑制剂

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/356,014 Continuation US9861636B2 (en) 2014-04-29 2016-11-18 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
US20160200730A1 US20160200730A1 (en) 2016-07-14
US9532990B2 true US9532990B2 (en) 2017-01-03

Family

ID=54358137

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/075,033 Active US9532990B2 (en) 2014-04-29 2016-03-18 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
US15/356,014 Active US9861636B2 (en) 2014-04-29 2016-11-18 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
US15/820,614 Active US10300066B2 (en) 2014-04-29 2017-11-22 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/356,014 Active US9861636B2 (en) 2014-04-29 2016-11-18 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
US15/820,614 Active US10300066B2 (en) 2014-04-29 2017-11-22 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors

Country Status (14)

Country Link
US (3) US9532990B2 (zh)
EP (1) EP3138842B1 (zh)
JP (2) JP6670756B2 (zh)
KR (2) KR20160144378A (zh)
CN (3) CN105017256A (zh)
AU (1) AU2015252654C1 (zh)
BR (1) BR112016025132A2 (zh)
CA (1) CA2947338C (zh)
EA (2) EA037227B1 (zh)
ES (1) ES2857251T3 (zh)
HK (1) HK1256857A1 (zh)
IL (1) IL248546B (zh)
MX (2) MX2016014248A (zh)
WO (1) WO2015165279A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170320879A1 (en) * 2014-11-19 2017-11-09 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
WO2019084369A1 (en) 2017-10-27 2019-05-02 Zhejiang DTRM Biopharma Co. Ltd. METHODS OF TREATING LYMPHOID MALIGNANCIES
US10300066B2 (en) * 2014-04-29 2019-05-28 Zhejiang DTRM Biopharma Co. Ltd. Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
US10537587B2 (en) 2015-03-19 2020-01-21 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014291161B2 (en) 2013-07-18 2018-04-26 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
EP3257855B1 (en) * 2015-02-12 2020-04-22 Shanghai Dude Medical Science and Technology Co., Ltd. Method for preparing ibrutinib
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技（苏州）有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
CN106146512B (zh) * 2015-04-09 2018-07-17 北京睿创康泰医药研究院有限公司 依鲁替尼的制备方法
WO2016168704A1 (en) 2015-04-16 2016-10-20 Icahn School Of Medicine At Mount Sinai Ksr antagonists
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP6959252B2 (ja) * 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
CN106146518A (zh) * 2016-06-30 2016-11-23 苏州爱玛特生物科技有限公司 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
EP3543239A1 (en) * 2016-11-15 2019-09-25 Hangzhou Hertz Pharmaceutical Co., Ltd. Selective bruton's tyrosine kinase inhibitor and use thereof
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
CN106831788B (zh) * 2017-01-22 2020-10-30 鲁南制药集团股份有限公司 伊布替尼精制方法
AU2018237123B2 (en) * 2017-03-22 2022-08-04 Xibin Liao Bruton's tyrosine kinase inhibitors
CN107501270B (zh) * 2017-09-01 2019-06-28 宏腾建设集团有限公司 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用
CN109970740A (zh) * 2017-12-27 2019-07-05 广东众生药业股份有限公司 4-氨基-嘧啶并氮杂环衍生物及其制备方法和用途
WO2020096042A1 (ja) * 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
CN111171035B (zh) * 2018-11-13 2021-03-30 山东大学 4-苯氧基苯基吡唑并嘧啶酰胺衍生物的制备方法和应用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
US20220386606A1 (en) 2019-03-15 2022-12-08 Bayer Aktiengesellschaft Specifically substituted 3-phenyl-5-spirocyclopentyl-3-pyrrolin-2-ones and their use as herbicides
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3964512A4 (en) * 2019-06-27 2022-08-10 Hangzhou Healzen Therapeutics Co., Ltd. CASEINKINASE-1-EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND ITS USE
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
LT4036095T (lt) 2019-09-26 2024-03-25 Jumbo Drug Bank Co., Ltd. 4-fluor-1h-pirazolo[3,4-c]piridino dariniai kaip selektyvūs brutono tirozino kinazės (btk) inhibitoriai, skirti gydyti b ląstelių limfomą ir autoimunines ligas
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP3865535A1 (en) 2020-02-11 2021-08-18 Bosti Trading Ltd. New method of synthesis of chitosan derivatives and uses thereof
TW202144465A (zh) 2020-02-11 2021-12-01 瑞士商諾和席卓股份有限公司 合成聚葡萄胺糖衍生物之新方法及其用途
AU2020436612A1 (en) * 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CN116075513A (zh) 2020-06-08 2023-05-05 哈利亚治疗公司 Nek7激酶的抑制剂
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
WO2022081512A1 (en) * 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
CN112574046A (zh) * 2020-12-17 2021-03-30 深圳市华先医药科技有限公司 一种制备(1r,3s)-3-氨基环戊醇盐酸盐的方法
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN117042769A (zh) * 2021-02-03 2023-11-10 冰洲石生物科技公司 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶
WO2023012333A2 (en) 2021-08-06 2023-02-09 Novochizol Sa Preparation of composite gels, polymer scaffolds, aggregates and films comprising soluble cross-linked chitosan & uses thereof
AR126678A1 (es) 2021-08-06 2023-11-01 Novochizol Sa Composiciones para el cuidado de las plantas y usos de las mismas
CN114605418B (zh) * 2022-03-15 2023-09-05 广东医科大学附属医院 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用
CN117430610A (zh) * 2023-10-11 2024-01-23 宁夏医科大学 一种氘代稠合杂环化合物及其制备方法和应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058944A1 (en) 2006-11-13 2008-05-22 Aeterna Zentaris Gmbh Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
WO2011046964A2 (en) 2009-10-12 2011-04-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120108612A1 (en) 2006-09-22 2012-05-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2012158764A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8673925B1 (en) 2013-04-09 2014-03-18 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2014168975A1 (en) 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
WO2014166820A1 (en) 2013-04-08 2014-10-16 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
CA2874756C (en) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
ES2660418T3 (es) * 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
CN102115476A (zh) * 2011-03-23 2011-07-06 常州大学 一种2H-吡唑并[3,4-d]嘧啶衍生物及合成方法
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
KR20140048968A (ko) * 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
ES2682043T3 (es) * 2012-07-30 2018-09-18 Concert Pharmaceuticals Inc. Ibrutinib deuterado
CN104540455A (zh) * 2012-07-31 2015-04-22 安全电线控股有限责任公司 深度可控的贾姆什迪针
US9266895B2 (en) * 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US9479134B2 (en) * 2013-03-04 2016-10-25 Texas Instruments Incorporated Position detecting system
CN105408334B (zh) * 2013-05-21 2017-10-10 江苏迈度药物研发有限公司 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120108612A1 (en) 2006-09-22 2012-05-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008058944A1 (en) 2006-11-13 2008-05-22 Aeterna Zentaris Gmbh Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
WO2011046964A2 (en) 2009-10-12 2011-04-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2012158764A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2014168975A1 (en) 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
WO2014166820A1 (en) 2013-04-08 2014-10-16 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
US8673925B1 (en) 2013-04-09 2014-03-18 Principia Biopharma Inc. Tyrosine kinase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Levy et al., "Dications of Fluorenylidenes. The Effect of Substituent Electronegativity and Position on the Antiaromaticity of Substituted Tetrabenzo[5.5]fulvalene Dications", J. Org. Chem., 2003, 68 (10), pp. 3990-3998.
Marostica, Eleonora, et al., "Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies," Cancer Chemother Pharmacol (2015) 75:111-121.
Roschewski, Mark, et al., "Diffuse large B-cell lymphoma-treatment approaches in the molecular era," Nature Reviews Clinical Oncology (advance online publication Nov. 12, 2013):1-12.
Shi et al, "Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases," Bioorganic & Medicinal Chemistry Letters (2014), pp. 2206-2211. *
Vargas et al, Scandinavian Journal of Immunology (2013), pp. 130-139. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300066B2 (en) * 2014-04-29 2019-05-28 Zhejiang DTRM Biopharma Co. Ltd. Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
US20170320879A1 (en) * 2014-11-19 2017-11-09 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
US10537587B2 (en) 2015-03-19 2020-01-21 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US10596183B2 (en) 2015-03-19 2020-03-24 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US11369620B2 (en) 2015-03-19 2022-06-28 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2019084369A1 (en) 2017-10-27 2019-05-02 Zhejiang DTRM Biopharma Co. Ltd. METHODS OF TREATING LYMPHOID MALIGNANCIES
US11622965B2 (en) 2017-10-27 2023-04-11 Zhejiang DTRM Biopharma Co. Ltd. Methods for treating lymphoid malignancies
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate

Also Published As

Publication number Publication date
US10300066B2 (en) 2019-05-28
JP2020040989A (ja) 2020-03-19
EA201892740A2 (ru) 2019-04-30
JP6670756B2 (ja) 2020-03-25
CN105017256A (zh) 2015-11-04
HK1256857A1 (zh) 2019-10-04
JP2017518276A (ja) 2017-07-06
CA2947338A1 (en) 2015-11-05
CN106061976A (zh) 2016-10-26
US20170065594A1 (en) 2017-03-09
CN108295073B (zh) 2020-06-16
US9861636B2 (en) 2018-01-09
MX2021013118A (es) 2023-01-24
EP3138842A4 (en) 2017-09-27
EA201892740A3 (ru) 2019-08-30
EA201692176A1 (ru) 2017-03-31
US20160200730A1 (en) 2016-07-14
KR20160144378A (ko) 2016-12-16
ES2857251T3 (es) 2021-09-28
CN106061976B (zh) 2018-05-15
JP7005582B2 (ja) 2022-01-21
BR112016025132A2 (pt) 2017-08-15
CA2947338C (en) 2022-12-20
AU2015252654B2 (en) 2019-10-03
AU2015252654C1 (en) 2020-01-23
CN108295073A (zh) 2018-07-20
IL248546A0 (en) 2016-12-29
AU2015252654A1 (en) 2016-11-03
EP3138842B1 (en) 2020-12-09
KR20230137499A (ko) 2023-10-04
MX2016014248A (es) 2017-05-30
US20180207161A1 (en) 2018-07-26
IL248546B (en) 2021-06-30
EA032100B1 (ru) 2019-04-30
WO2015165279A1 (zh) 2015-11-05
EP3138842A1 (en) 2017-03-08
EA037227B1 (ru) 2021-02-24

Similar Documents

Publication Publication Date Title
US10300066B2 (en) Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
US10537587B2 (en) Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US10973817B2 (en) Pharmaceutical compounds
US10781205B2 (en) Conjugates comprising RIPK2 inhibitors
EP3272752A1 (en) Optimised combination therapy and use thereof to treat cancer and autoimmune disease
US20230312586A1 (en) Heterobicyclic amides as inhibitors of cd38
EP2804861B1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
US11384066B1 (en) Heterocyclic compounds useful as aurora a selective inhibitors
US20230192734A1 (en) Tricyclic compounds as egfr inhibitors
TW201446767A (zh) 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
WO2015091532A1 (en) Pyrrolopyrimidine derivatives as pi3k inhibitors
US20240101540A1 (en) Targeted protein degradation of parp14 for use in therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZHEJIANG DTRM BIOPHARMA CO. LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HE, WEI;REEL/FRAME:040290/0782

Effective date: 20161111

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: SHENZHEN GREEN PINE GROWTH NO. 1 EQUITY INVESTMENT

Free format text: SECURITY INTEREST;ASSIGNOR:ZHEJIANG DTRM BIOPHARMA CO. LTD.;REEL/FRAME:043686/0925

Effective date: 20170921

AS Assignment

Owner name: SHENZHEN GREEN PINE GROWTH NO. 1 EQUITY INVESTMENT

Free format text: TERMINATION AND RELEASE OF PATENT ASSIGNMENT;ASSIGNOR:ZHEJIANG DTRM BIOPHARMA CO. LTD.;REEL/FRAME:045141/0001

Effective date: 20180121

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4